Recent therapeutic advances have changed the treatment landscape of metastatic renal cell carcinoma. Unfortunately, the seven agents now available are not based on biomarkers that would indicate ...

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of ...

Prostate-specific membrane antigen (PSMA) gene expression predicts angiogenesis and response to tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC), ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...